- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01924962
Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries (REVASC)
November 3, 2017 updated by: Dr. Heinz Joachim Buettner, University Heart Center Freiburg - Bad Krozingen
A Randomized Comparison of Recanalisation With Implantation of Cypher Sirolimus Eluting Coronary Stents and Medical Therapy
The study is a randomised comparison of recanalisation of chronic occluded coronary arteries with implantation of Sirolimus eluting stents and medical therapy.
Myocardial function and scar-size are determinated by using magnetic resonance imaging.
The study hypothesis is the superiority of medical therapy over revascularisation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In the REVASC-study recovery of left ventricular function after recanalization of chronic total coronary occlusions (CTO) and implantation of sirolimus-eluting stents will be examined and compared to medical treatment.
Extent of the scar, viable myocardium in the infarct zone and regional left ventricular function will be assessed by cardiac magnetic resonance.
Patients with regional systolic left ventricular dysfunction of any degree in the supply territory of the CTO vessel will be randomized to either recanalization of the occluded coronary artery or to conservative therapy.
It is of interest whether CTO patients will have an improvement in left ventricular function after late coronary reopening, regarding the high technical demands and costs of CTO recanalization.
Study Type
Interventional
Enrollment (Actual)
205
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baden-Württemberg
-
Bad Krozingen, Baden-Württemberg, Germany, 79189
- Universitäts Herzzentrum Freiburg Bad Krozingen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- chronic total occlusion with thrombolysis in myocardial infarction (TIMI) 0 flow (or distal capillary reflow) of a native coronary artery with an estimated reference vessel diameter of 2.5 to 4.0 mm
- chronic total occlusion has more than 4 weeks duration
- the target vessel has not previously been treated with percutaneous coronary intervention
- the target vessel must be feasible for stent implantation
- patient has stable or unstable angina pectoris or a positive functional study for ischemia
- patient must be 18 years of age or older
- female subjects of childbearing age must have a negative pregnancy test within 7 days before procedure
- patient has been informed of the nature of the study and agrees to its
- provisions ans has written informed consent as approved by the Ethics Committee
- patient complies with all required post-procedure follow-up
Exclusion Criteria:
- a documented left ventricular function < 30%
- patient has a acute myocardial infarction (>3x normal creatine kinase (CK with presence of CK-MB) within 72 hours preceding the index procedure and CK has not returned to normal limits at the time of the procedure
- patients with known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, stainless steel or contrast media that cannot be adequately been pre-medicated
- patient has a platelet count of < 100000 cells/mm3 or > 700000 cells/m3, a white blood cell count of < 3000 cells/mm3 or documented or suspected liver disease
- patient has a history of bleeding diathesis or coagulopathy
- patient has suffered a cerebrovascular accident or transient ischemic attack within the past 6 months
- active peptic ulcer or upper gastrointestinal bleeding within the prior 6 months
- patients has a co-morbidity (i.e. cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, or is associated with limited life-expectancy (less than 2 years)
- the target vessel contains intraluminal thrombus
- the target vessel or lesson shows angiographic evidence of severe calcification
- patient has contraindications to magnetic resonance imaging
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: medical therapy
patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
|
|
|
Active Comparator: revascularisation
revascularisation and stent-implantation of chronic occluded coronary artery
|
revascularisation of chronic occluded coronary artery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline in regional left ventricular function at 9 months
Time Frame: 9 months
|
Improvement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure.
For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in global left ventricular function at 6 months
Time Frame: 6 months
|
Improvement of global left ventricular function (assessed by magnetic resonance imaging at baseline and 9 months post-procedure.
For global left ventricular analysis, all short-axis slices from the apex to the base will be assessed.
By planimetry of all short-axis views, left ventricular end-systolic volume (in milliliters), left ventricular end-diastolic volume (in milliliters), and ejection fraction (in percent) will be determined.
|
6 months
|
|
Changes from baseline in left ventricular volume at 6 months
Time Frame: 6 months
|
Changes in diastolic and systolic volume indices (assessed by magnetic resonance imaging at baseline and 9 months post-procedure)
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Heinz Joachim Buettner, MD, Universitaets-Herzzentrum Freiburg-Bad Krozingen, Clinics for Cardiology and Angiology II, D-79189 Bad Krozingen, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 28, 2008
Primary Completion (Actual)
August 14, 2016
Study Completion (Actual)
June 16, 2017
Study Registration Dates
First Submitted
August 15, 2013
First Submitted That Met QC Criteria
August 16, 2013
First Posted (Estimate)
August 19, 2013
Study Record Updates
Last Update Posted (Actual)
November 7, 2017
Last Update Submitted That Met QC Criteria
November 3, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BK 1-2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Heart Disease
-
Shenyang Northern HospitalRecruitingCoronary Heart Disease (CHD)China
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Chang Gung University of Science and TechnologyChang Gung Memorial Hospital; Chang Gung University; National Science and Technology...Enrolling by invitationCoronary Heart Disease (CHD) | Coronary Arterial Disease (CAD)Taiwan
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Tung Wah CollegeRecruitingCoronary Heart Disease (CHD)Hong Kong
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Tsinghua UniversityNot yet recruitingCoronary Heart Disease (CHD)
-
MedImmune LLCCompletedStable Coronary Heart DiseaseUnited States
-
Medical University of LodzBaxter Healthcare CorporationUnknownCHD - Coronary Heart DiseasePoland
-
University of ZurichCompletedStable Coronary Heart DiseaseSwitzerland
Clinical Trials on revascularisation
-
RenJi HospitalRecruiting
-
Naveen SeecheranCompletedLimb Salvage Rates With Endovascular TherapyTrinidad and Tobago
-
Helios Health Institute GmbHHeart Center Leipzig - University Hospital; IHF GmbH - Institut für HerzinfarktforschungCompletedAcute Myocardial Infarction | Cardiogenic ShockSlovenia, Germany
-
Kolding SygehusOdense University Hospital; Regionshospitalet Holstebro, Holstebro, DenmarkUnknownHeart Failure | Aortic Stenosis | Healthy Volunteers | Ischemic Heart Disease | Pulmonary HypertensionDenmark
-
University Hospitals, LeicesterUniversity of East Anglia; British Heart Foundation; University of LeicesterTerminatedCardiovascular; AttackUnited Kingdom
-
Maasstad HospitalAbbott Medical DevicesCompletedMyocardial Infarction | Multivessel Coronary Artery DiseaseNorway, Netherlands, Poland, Singapore, Germany, Czechia, Hungary, Sweden
-
Clinica Universidad de Navarra, Universidad de...Fina BiotechTerminated
-
MedtronicTerminatedAngina PectorisUnited Kingdom
-
Nantes University HospitalRecruiting
-
Ulrich Ronellenfitsch, MDTerminated